Ontorpacept Biosimilar Fusion Protein (CD47) for Research
Pre-Made Ontorpacept Biosimilar, Fusion Protein targeting CD47 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting IAP/MER6/OA3 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ontorpacept is a fusion protein consisting of Signal regulatory protein α (SIRPα) fused to the human IgG1 Fc region, that binds to CD47 and blocks inhibitory signaling to macrophages, resulting in increased phagocytosis of tumor cells
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-937-1mg | 1mg | 3090 |
| GMP-Bios-INN-937-10mg | 10mg | |
| GMP-Bios-INN-937-100mg | 100mg | |
| GMP-Bios-INN-937-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Ontorpacept Biosimilar, Fusion Protein targeting CD47 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting IAP/MER6/OA3 |
| INN Name | Ontorpacept |
| Target | CD47 |
| Format | Fusion Protein |
| Derivation | human |
| Species Reactivity | human |
| CH1 Isotype | Fusion - SIRPA (signal regulatory protein alpha, SHPS1, SIRP, SIRPalpha) - IGHG1 (Fc (Fragment constant) |
| VD LC | Fusion - SIRPA (signal regulatory protein alpha, SHPS1, SIRP, SIRPalpha) - IGHG1 (Fc (Fragment constant) |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Trillium Therapeutics Inc. (Mississauga Canada) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
About target - CD47
1. Protein Leukocyte surface antigen CD47
2. Gene CD47
3. Organism Homo sapiens (Human)
Function
Has a role in both cell adhesion by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins. Plays an important role in memory formation and synaptic plasticity in the hippocampus (By similarity).
Receptor for SIRPA, binding to which prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and costimulates T-cell activation. May play a role in membrane transport and/or integrin dependent signal transduction. May prevent premature elimination of red blood cells. May be involved in membrane permeability changes induced following virus infection.

